No Data
No Data
HK stock market surge | Hepalink (09989) rose over 4%, net profit for the first half of the year is expected to increase by more than 4.2 times, and sales of enoxaparin sodium preparations continue to increase steadily.
Hepalink (09989) surged over 4%, as of press time, up 4.55% to HKD 3.68, with a turnover of 4.3864 million Hong Kong dollars.
Despite the net profit of hepalink (09989) soaring 4.2 times year-on-year, can it only rise and fall during the heparin cycle?
In 2023, with the return of global heparin business, the low baseline performance became the stepping stone for Hepalink now.
Is Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) A Risky Investment?
HKEx News | Hepalink (09989) soared more than 14%, and its net profit for the first half of the year is expected to increase by more than 4.2 times year-on-year.
According to the Zhicheng Financial APP, Hepalink (09989) rose more than 14%. As of press time, it rose 14.2% to HKD 3.76, with a turnover of HKD 1.9479 million. In terms of news, Hepalink announced that it is expected that the group will achieve a net income attributable to shareholders of the listed company of approximately RMB 0.642 billion to 0.735 billion in the first half of 2024, a year-on-year increase of 420.70%-495.72%; the expected non-deductible net profit will be approximately RMB 0.308 billion to 0.401 billion, a year-on-year increase of 286.96%-403.20%. The company pointed out that its main product during the reporting period is Enoxaparin Sodium.
Shenzhen Hepalink Pharmaceutical Group: 2024 Interim Performance Forecast
Shenzhen Hepalink Pharmaceutical's Profit to Soar Nearly 500% in H1
No Data